NICE offers a second look at denosumab . . .

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.656, 2012-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Positive NICE recommendations for rivaroxaban and denosumab

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 651, 2012-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

A closer look at the NICE cost-effectiveness threshold

Inpharma, Vol. 1, Iss. 1659, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

A closer look at the NICE cost-effectiveness threshold

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 564, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women: A NICE Single Technology Appraisal

By Scotland Graham

PharmacoEconomics, Vol. 29, Iss. 11, 2011-11 ,pp. : 951-961

Adis International

Access to resources Recommend Favorite

The UK NICE has not recommended everolimus [Afinitor] as second-line treatment for advanced renal cell carcinoma.

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 627, 2011-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite